butabarbital decreases results of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of CYP3A4 inducers may possibly minimize sufentanil ranges and efficacy, potentially precipitating withdrawal syndrome in people that have design